

DIASORIN COMPLETES THE ACQUISITION OF THE ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS

Saluggia (Italy), September 29th, 2017 - DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA) announces the completion of the transaction to acquire from Siemens Healthcare GmbH and affiliated companies (“**Siemens Healthineers**”) its micro-titre based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, initiated with a binding purchase agreement signed on July 25th, 2017.

The purchased Siemens Healthineers ELISA immunodiagnostic business portfolio and the associated tangible and intangible assets include mainly the customers’ sales and distribution contracts, the installed base of instruments and the relevant intellectual property. The acquisition did not include the transfer of employees nor manufacturing facility and capability.

Siemens Healthineers will continue to manufacture and provide exclusively to DiaSorin its ELISA immunodiagnostic reagent kits for a period of up to 3 years enabling a continuous supply to customers with the current Siemens Healthineers ELISA immunodiagnostic products.

The transaction’s main terms and conditions are those already made available by DiaSorin to the public on July 25th, 2017.

About DiaSorin

Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field.

For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide.

Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For more information, please visit www.diasorin.com

For additional information, please contact:

Riccardo Fava

Investor Relations & Corporate Communication Senior Director

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator

Tel: +39.0161.487567

ines.diterlizzi@diasorin.it